Fiche publication
Date publication
mai 2016
Journal
Lung cancer (Amsterdam, Netherlands)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand
Tous les auteurs :
Sassier M, Mennecier B, Gschwend A, Rein M, Coquerel A, Humbert X, Alexandre J, Fedrizzi S, Gervais R
Lien Pubmed
Résumé
We report two cases of acute hepatitis induced by crizotinib in patients with ALK-rearranged non-small cell lung cancer (NSCLC) who were treated after by a second generation of ALK inhibitor without any incident. These cases suggest that ceritinib could be used as an alternative agent when crizotinib is responsible for hepatitis.
Mots clés
Adult, Antineoplastic Agents, adverse effects, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Carcinoma, Non-Small-Cell Lung, complications, Drug Substitution, Female, Hepatitis, diagnosis, Humans, Lung Neoplasms, complications, Male, Middle Aged, Protein Kinase Inhibitors, adverse effects, Pyrazoles, adverse effects, Pyridines, adverse effects, Pyrimidines, therapeutic use, Receptor Protein-Tyrosine Kinases, antagonists & inhibitors, Sulfones, therapeutic use, Treatment Outcome
Référence
Lung Cancer. 2016 May;95:15-6
